Gilead Sciences Presents Real-World Data for Sunlenca in Heavily Treatment-Experienced HIV Patients

Gilead Sciences today presented real-world evidence from multiple clinical sites showing that Sunlenca (lenacapavir) achieves and maintains viral suppression in heavily treatment-experienced people with HIV who have limited treatment options. The data showed that approximately 75% of patients achieved HIV RNA below 50 copies/mL at 48 weeks.